Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) was the target of a large decline in short interest in the month of October. As of October 30th, there was short interest totaling 82,127 shares, a decline of 49.5% from the October 15th total of 162,704 shares. Currently, 1.5% of the shares of the company are short sold. Based on an average trading volume of 1,493,800 shares, the days-to-cover ratio is currently 0.1 days.
Analyst Ratings Changes
A number of brokerages recently weighed in on SLXN. Maxim Group cut shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. Wall Street Zen upgraded shares of Silexion Therapeutics to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Friday, September 11th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.
Read Our Latest Stock Analysis on SLXN
Silexion Therapeutics Trading Down 4.0%
Shares of NASDAQ:SLXN traded down $0.08 during midday trading on Monday, hitting $1.90. The stock had a trading volume of 10,054 shares, compared to its average volume of 134,841. The company has a market capitalization of $440,800.00, a PE ratio of -0.04 and a beta of -0.30. The stock has a 50 day moving average price of $5.70 and a two-hundred day moving average price of $140.28. Silexion Therapeutics has a 1 year low of $1.82 and a 1 year high of $777.12.
Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($13.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($218.40) by $204.70. As a group, equities analysts expect that Silexion Therapeutics will post -112.71 EPS for the current year.
Silexion Therapeutics Company Profile
Silexion Therapeutics Ltd. (NASDAQ: SLXN) is an Israel-based clinical-stage biotechnology company developing RNA-based medicines for the treatment of solid tumors driven by mutations in the KRAS oncogene. The company’s technology is designed to selectively silence cancer-causing KRAS mutations while limiting exposure to healthy tissue. Silexion’s lead program, siG12D-LODER, is an investigational RNA interference therapy targeting the KRAS G12D mutation, which is frequently found in pancreatic and other difficult-to-treat cancers.
See Also
- Five stocks we like better than Silexion Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Silexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
